• Syndax Pharmaceuticals recently held an R&D event where it outlined its late-stage programs, including revumenib and axatilimab, and introduced two new candidates: SNDX-4321, an allosteric EGFR inhibitor for EGFR-mutant NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis, with multiple IND submissions and early-stage trials planned through 2027.
• A key insight is Syndax’s move to diversify beyond its two main commercial assets by licensing SNDX-4321 and advancing a wholly owned next-generation menin platform, aiming to extend its reach into difficult-to-treat solid tumors and hematologic diseases with significant unmet need.
• We’ll now assess how the introduction of SNDX-4321, a novel allosteric EGFR inhibitor, could reshape Syndax’s existing investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Syndax Pharmaceuticals Investment Narrative Recap

To own Syndax, you need to be comfortable with a story still anchored in Revuforj and Niktimvo while the company runs at a net loss to fund growth. The R&D event broadens the pipeline with SNDX-4321 and SNDX-62122, but it does not change that the key near term catalyst is additional label and guideline momentum for Revuforj, and the main risk remains any clinical, regulatory, or reimbursement setback to the two commercial franchises.

The most relevant recent update here is the dense stream of Revuforj data at EHA and ASCO 2026, including the SAVE trial publication and multiple frontline and maintenance abstracts. Together with the new menin program SNDX-62122, these data help frame how Syndax is trying to deepen and then extend its menin franchise, which is central to both its near term revenue catalysts and its longer term effort to reduce dependence on just two products.

Yet beneath the attractive new assets, investors should be aware that Syndax’s continued heavy reliance on Revuforj and Niktimvo still leaves it exposed to...

Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.

Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 74% upside to its current price.

Exploring Other Perspectives

Before this R&D update, the most bullish analysts were already projecting about US$942,100,000 of revenue and US$182,700,000 of earnings by 2029, so if you are using those optimistic assumptions, the introduction of SNDX-4321 and SNDX-62122 could either reinforce that view or highlight how much still hinges on their shared concern about rising R&D costs and cash burn.

Explore 5 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth over 7x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.